

1 **Procalcitonin to Predict Severity of Acute Cholangitis and Need for Urgent Biliary**

2 **Decompression: Systematic Scoping Review**

3

4

5 Krixie Silangcruz<sup>1</sup>, Yoshito Nishimura<sup>1</sup>, Torrey Czech<sup>1</sup>, Nobuhiko Kimura<sup>1</sup>, James Yess<sup>1</sup>

6

7 <sup>1</sup>Department of Medicine, John A. Burns School of Medicine, University of Hawai'i, Honolulu,

8 HI, 96813, USA

9

10

11 **Keywords:** procalcitonin, acute cholangitis, scoping review, systematic review

12

13 **\*Corresponding author**

14 Yoshito NISHIMURA, MD, PhD, MPH

15 1356 Lusitana St., Room 715, Honolulu, HI 96813, USA

16 Tel.: +1-808-203-6530; Fax: +1-808-955-2174

17 E-mail: yoshiton@hawaii.edu

18

19

20 **Abstract**

21 **Background:** Serum Procalcitonin (PCT) has been reported as a potential biomarker to predict the  
22 severity of acute cholangitis (AC) or the need for urgent biliary decompression. This study aimed  
23 to identify and summarize the existing research about the serum PCT and the severity of AC, and  
24 to find gaps where future studies can be targeted towards.

25 **Methods:** Following the PRISMA Extension for Scoping Reviews, MEDLINE, EMBASE, and  
26 Google Scholar were searched for all peer-reviewed articles with relevant keywords including  
27 “cholangitis” and “procalcitonin” from their inception to July 13, 2021.

28 **Results:** We identified six studies. All the studies employed case-control design and aimed to  
29 evaluate the usefulness of serum PCT to predict the severity of AC with key identified outcomes.  
30 While potential cut-off values of serum PCT for severe AC ranged from 1.8–3.1 ng/mL, studies  
31 used different severity criteria and the definition of urgent biliary decompression. No studies  
32 proposed cut-off PCT values for the need for urgent biliary decompression.

33 **Conclusion:** This scoping review identified that the current level of evidence regarding the  
34 usefulness of serum PCT in assessing the severity of AC. Further clinical research is warranted  
35 with a focus on standardized outcome measures employing prospective or experimental designs.

36

37

## 38 **Introduction**

39 Acute cholangitis (AC) is a medical emergency and systemic condition due to biliary infection and  
40 obstruction with an associated high mortality rate<sup>1, 2</sup>. Before advancements in critical care and  
41 decompression of the biliary duct system, the mortality of AC was reported to be over 50%<sup>2</sup>.  
42 Subsequent to 1980, the mortality rates of AC ranged from 10-30%, with multiorgan failure noted  
43 to be the cause of death<sup>3</sup>. The majority of cases of AC are due to biliary duct stones. The variety of  
44 additional etiologies underscores a wide variety of risk factors that influence mortality<sup>3, 4</sup>.

45  
46 Procalcitonin (PCT), a 116 amino acid peptide precursor of calcitonin, is initially thought to help  
47 identify sepsis patients and was later associated with bacterial infection<sup>5</sup>. However, its role in  
48 disease severity prediction remains unclear<sup>6</sup>, with a reported sensitivity and specificity of PCT to  
49 predict septic shock of any causes 63% and 65%, respectively<sup>7</sup>. Thus, the use of PCT in the  
50 diagnosis of sepsis remains a topic of contentious debate<sup>8</sup>.

51  
52 Various studies have found PCT to be correlated with the disease severity of AC. The Tokyo  
53 Guidelines 2018 (TG18) for AC discussed the utility of PCT as a parameter for the severity  
54 assessment, stating that there was level D (very low-quality) evidence, and it might be an area of  
55 future research<sup>9</sup>. So far, small-scale studies have been conducted to examine the usefulness of

56 serum PCT values to predict the severity of AC or the need for urgent biliary decompression, using  
57 either Tokyo Guidelines 2007 (TG07) and Tokyo Guidelines 2013 (TG13)<sup>10-15</sup>. However, to date,  
58 no systematic reviews are available to analyze the evidence from studies across different settings  
59 and clinical outcomes to identify the trends of PCT in AC or limitations with current literature to  
60 generate recommendations in this area for future research.

61  
62 The objective of this study is to scope the states of research to determine the relationship between  
63 serum PCT levels and AC disease severity, trends correlating PCT levels to different hierarchical  
64 levels of intervention as well as the need for urgent biliary decompression to identify directions for  
65 future research in this area.

66

## 67 **Methods**

### 68 **Study Design**

69 This is a systematic scoping review conducted in accordance with the Preferred Reporting Items  
70 for Systematic Reviews and Meta-Analyses (PRISMA) extension for scoping reviews  
71 (PRISMA-ScR)<sup>16, 17</sup>. See **Appendix 1** for PRISMA-ScR Checklist of the present study.

72

### 73 **Search Strategy**

74 We searched MEDLINE, EMBASE, and Google Scholar for all peer-reviewed articles and  
75 conference abstracts from inception to July 13<sup>th</sup>, 2021. No filters for study design and language  
76 were used. A manual screening for additional pertinent articles was done using the reference lists  
77 of all articles that met the eligibility criteria. The search strategy involved relevant keywords,  
78 including “cholangitis” and “procalcitonin.” The search was conducted by two authors (YN and  
79 NK) independently. See **Appendix 2** for detailed search terms.

80

## 81 **Eligibility Criteria**

82 The criteria for the inclusion of articles are the following:

83 (1) Peer-reviewed articles evaluating the relationship between serum procalcitonin levels and  
84 severity of acute cholangitis or need for biliary decompression.

85 (2) Randomized controlled trials (RCTs), case-control studies, cohort studies (prospective or  
86 retrospective), cross-sectional studies, and case series in adult patients

87 The exclusion criteria included the following:

88 (1) Qualitative studies, review articles, case reports, and commentaries.

89 (2) Conference abstracts

90 (3) Studies involving pediatric or obstetric patients.

91

## 92 **Study Selection**

93 Articles selected for full-text assessment were assessed independently by YN and NK using  
94 EndNote 20 reference management software. Articles considered eligible were then evaluated in  
95 full length with the inclusion and exclusion criteria.

96

## 97 **Data Extraction**

98 A standardized data collection form that followed the PRISMA and Cochrane Collaboration  
99 guidelines for systematic reviews was used to obtain the following information from each study:  
100 title, name of authors, year of publication, country of origin, study characteristics, target outcome,  
101 aims, study and comparative groups, key findings, and limitations.

102

## 103 **Results**

### 104 **Search Results and Study Selection**

105 **Figure 1** shows a PRISMA flow diagram that depicts the process of identification, screening,  
106 eligibility, and inclusion or exclusion of the studies. The initial search of MEDLINE, EMBASE  
107 and Google Scholar yielded 1987 articles. 62 duplicate studies were removed, followed by the  
108 elimination of 1900 articles that were either irrelevant to our study, review articles, editorial  
109 articles, or conference abstracts with title and abstract screening. Subsequently, 25 articles

110 underwent a full-text review. Of these articles, 19 articles were because they were review articles,  
111 did not investigate the need for biliary drainage or cholangitis severity as an outcome, did not  
112 measure procalcitonin in the participants, or were not studies about procalcitonin and acute  
113 cholangitis. One study was also excluded because of the discrepancy between the data presented  
114 in the main text and the figures.

115

### 116 **Description of Included Studies**

117 A total of six studies met our eligibility criteria for the scoping review<sup>10-12, 14, 18, 19</sup>. The main  
118 characteristics of the included studies are described in **Table 1**. Five were retrospective  
119 case-control studies, while one study<sup>12</sup> used a prospective case-control design. All the studies were  
120 from Asia (Japan, n = 4; South Korea, n = 1; China, n = 1). Sample sizes varied from 58 to 213  
121 participants. All studies aimed to evaluate the usefulness of PCT to predict the severity of AC and  
122 were based on data from a single center.

123

### 124 **Outcomes**

125 Four studies also assessed blood culture positivity among participants<sup>11, 12, 14, 19</sup>. The number of  
126 patients who went through urgent biliary decompression was reported in three studies<sup>12, 14, 19</sup>. Of

127 the three studies, a study by Lee et al. and Umefune et al. reported timing of biliary  
128 decompression<sup>12, 14</sup>. 4 studies assessed positivity of blood culture in patients with AC<sup>11, 12, 14, 19</sup>.

129

### 130 **Severity of Acute Cholangitis**

131 Findings related to serum PCT levels and the severity of AC or other pertinent outcomes are  
132 summarized in **Table 2**. Except for one study<sup>10</sup>, TG13 Guidelines were used as the Severity  
133 Criteria of AC. There was a significant variation in the proportion of patients with severe AC  
134 from 7/122 (5.7%)<sup>19</sup> to 25/110 (22.7%)<sup>11</sup>. All studies reported that serum PCT levels were  
135 significantly higher in those with severe AC than those with mild or moderate AC, although the  
136 median serum PCT level differed considerably among the included articles. Area under the  
137 receiver operator characteristic (AU-ROC) of serum PCT for severe AC varied from 0.75 (95%  
138 confidence interval [CI] 0.63–0.87)<sup>11</sup> from 0.90 (95%CI 0.85–0.96)<sup>12</sup>. Except for one study<sup>19</sup>,  
139 potential cut-off values of serum PCT for severe AC were proposed, which ranged from 1.76  
140 ng/mL (sensitivity 84.6%, specificity 62.4%) from 3.1 ng/mL (sensitivity 80.8%, specificity  
141 84.6%)<sup>10</sup> using the Youden Index method, with three studies that reported similar cut-off values  
142 (Umefune et al. 2.2 ng/mL, Shinya et al. 2.33 ng/mL, Lyu et al. 2.38 ng/mL).

143

### 144 **Procalcitonin and Urgent Biliary Decompression**



145 Although some studies included the term “biliary drainage” or “biliary decompression”<sup>11, 14</sup>, no  
146 studies proposed potential cut-off values for the need for urgent or emergent biliary decompression.  
147 The surrogate of the need for urgent or emergent biliary decompression varied considerably  
148 among the studies. Korekawa et al.<sup>11</sup> used thrombocytopenia as the surrogate and suggested that  
149 the cut-off serum PCT to predict lower platelet counts (1.3 ng/mL) might also be helpful to  
150 determine those who may need urgent biliary decompression. Shinya et al.<sup>11</sup> proposed a cut-off  
151 PCT for the presence of purulent bile juice on biliary decompression (3.2ng/mL) as the surrogate.  
152 Other studies used the severity of AC as the surrogate for the need for urgent biliary  
153 decompression. Of note, the definitions of urgent or emergent decompression were different  
154 among the articles. Korekawa et al. defined “emergent endoscopic retrograde  
155 cholangiopancreatography (ERCP)” as “the procedures done within 24 hours after admission”,  
156 while Umefune et al. defined urgent and early biliary drainage as “biliary drainage six hours and  
157 12 hours after admission”, respectively. Other studies did not specify the term of early, urgent, or  
158 emergent biliary decompression.

159

## 160 **Discussion**

161 In this scoping review, we identified six primary studies related to serum PCT levels and the  
162 severity of AC or other pertinent outcomes such as blood culture positivity, progression to septic

163 shock, need, and timing of biliary decompression, or biliary fluid character on ERCP. All studies  
164 reported that serum PCT levels were significantly higher in those with severe AC than those with  
165 mild or moderate diseases, although the median serum PCT levels were considerably different  
166 among the included articles.

167  
168 AC requires appropriate treatment in the early phase because severe AC may result in death if no  
169 early appropriate medical care is provided. Historically, TG13 proposed management bundles of  
170 AC, and TG18 re-defined the management bundles and mentioned the potential utility of serum  
171 PCT in predicting the severity of AC<sup>15, 20</sup>. These guidelines classified the severity of AC into three  
172 grades; mild (grade I), moderate (grade II), and severe (grade III)<sup>21</sup>. In particular, TG18 severity  
173 grading criteria for AC are essential for predicting prognosis and determining a treatment strategy  
174 by identifying patients requiring early biliary drainage, although its ability to identify those who  
175 need the procedure is limited<sup>22</sup>. As noted above, there was very low-quality evidence suggesting  
176 the utility of PCT as a parameter for the severity assessment of AC when TG18 was proposed.  
177 Despite a suggestion that PCT might be a better biomarker to predict the severity of AC than white  
178 blood cell or C-reactive protein<sup>12</sup>, unfortunately, however, there is still limited evidence regarding  
179 the point, although three years have passed since TG18.

180

181 The present study results showed that previous literature had a certain degree of consistency  
182 regarding a potential serum PCT cut-off value for severe AC (ranged from approximately 1.8  
183 ng/mL to 3.1 ng/mL) with satisfactory AU-ROC. However, all the studies had different  
184 limitations, as described in **Table 1**. While the proposed serum PCT cut-off values for severe AC  
185 were similar, median PCT values of either moderate or severe AC differed considerably among the  
186 included studies. Of note, no studies proposed cut-off values to proceed with urgent biliary  
187 decompression, and the severity of AC was used as a surrogate of the need for the procedure. Of  
188 note, there were inconsistencies in the severity criteria used (Hamano et al. used TG07 and the  
189 others employed TG13) and the definition of either “urgent” or “emergent” decompression. For  
190 example, Umefune et al. defined urgent biliary drainage as “within 6 hours from admission”, while  
191 Lee et al. classified patients according to the timing of biliary drainage; within 24 hours, from 24 to  
192 48 hours, or after 48 hours from a hospital visit. The differences in the guidelines used and the  
193 outcome measurements negatively affect the level of evidence.

194

195 Other limitations of the studies include that all of the currently available research were  
196 case-control studies (five retrospective and one prospective) with small sample sizes. Also,  
197 considerable heterogeneity of basic demographics among the studies needs to be noted. All the  
198 studies were conducted in Asian countries, including Japan, South Korea, and China. Further, the

199 etiology of AC may be different; for instance, 9.8% of patients in the study by Lee et al. had  
200 malignant biliary strictures, while Shinya et al. included only patients with choledocholithiasis. All  
201 the factors limit the generalizability of the results. Future studies may need adequate power with a  
202 prospective design and standardized outcome measurements, using the same severity criteria and  
203 the definition of urgent biliary decompression. Non-randomized controlled trial comparing the  
204 outcome of those with or without urgent biliary decompression might be necessary to establish a  
205 cut-off serum PCT value to determine the need for the procedure.

206  
207 Several limitations in this study should be noted. First, due to the urgent need for evidence on  
208 this topic and limited time, we did not contact authors to clarify the details of data described in  
209 literature. Second, we only included peer-reviewed articles in this scoping review. Thus,  
210 non-peer-reviewed articles or conference abstracts, which might be useful, were excluded from  
211 the study. To the best of our knowledge, however, there has been no scoping review to  
212 investigate the utility of serum PCT to predict the severity of AC or the need for biliary  
213 decompression.

214  
215 In conclusion, this scoping review identified that the current body of evidence regarding the  
216 usefulness of serum PCT in assessing the severity of AC, and potential cut-off values for the need

217 for urgent biliary decompression, remains scarce. In the future, further clinical research employing  
218 prospective or experimental designs is imperative to determine practical cut-off values for serum  
219 PCT for severe AC and the need for early biliary decompression.

220

#### 221 **Conflicts of Interest**

222 The authors declare no conflicts of interest in association with the present study.

223

#### 224 **Funding**

225 None.

226

#### 227 **Author contributions**

228 KS conceived the study and drafted the manuscript. YN searched the literature, assessed the  
229 quality of the studies, drafted and revised the manuscript. TC performed data interpretation,  
230 drafted and revised the manuscript. NK searched the literature and revised the manuscript. JY  
231 revised the manuscript.

232

233

234

235

236 **References**

237 1. Lan Cheong Wah D, Christophi C, Muralidharan V. Acute cholangitis: current concepts.

238 ANZ J Surg. 2017;87(7-8):554-9.

239 2. Sulzer JK, Ocuin LM. Cholangitis: Causes, Diagnosis, and Management. Surg Clin

240 North Am. 2019;99(2):175-84.

241 3. Kimura Y, Takada T, Kawarada Y, Nimura Y, Hirata K, Sekimoto M, et al. Definitions,

242 pathophysiology, and epidemiology of acute cholangitis and cholecystitis: Tokyo Guidelines. J

243 Hepatobiliary Pancreat Surg. 2007;14(1):15-26.

244 4. Sokal A, Sauvanet A, Fantin B, de Lastours V. Acute cholangitis: Diagnosis and

245 management. J Visc Surg. 2019;156(6):515-25.

246 5. Hamade B, Huang DT. Procalcitonin: Where Are We Now? Crit Care Clin.

247 2020;36(1):23-40.

248 6. Aloisio E, Dolci A, Panteghini M. Procalcitonin: Between evidence and critical issues.

249 Clin Chim Acta. 2019;496:7-12.

250 7. Yunus I, Fasih A, Wang Y. The use of procalcitonin in the determination of severity of

251 sepsis, patient outcomes and infection characteristics. PLOS ONE. 2018;13(11):e0206527.

252 8. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic

- 253 marker for sepsis: a systematic review and meta-analysis. *Lancet Infect Dis.* 2013;13(5):426-35.
- 254 9. Yokoe M, Hata J, Takada T, Strasberg SM, Asbun HJ, Wakabayashi G, et al. Tokyo  
255 Guidelines 2018: diagnostic criteria and severity grading of acute cholecystitis (with videos). *J*  
256 *Hepatobiliary Pancreat Sci.* 2018;25(1):41-54.
- 257 10. Hamano K, Noguchi O, Matsumoto Y, Watabe T, Numata M, Yosioka A, et al.  
258 Usefulness of procalcitonin for severity assessment in patients with acute cholangitis. *Clinical*  
259 *laboratory.* 2013;59(1-2):177-83.
- 260 11. Shinya S, Sasaki T, Yamashita Y, Kato D, Yamashita K, Nakashima R, et al.  
261 Procalcitonin as a useful biomarker for determining the need to perform emergency biliary  
262 drainage in cases of acute cholangitis. *J Hepatobiliary Pancreat Sci.* 2014;21(10):777-85.
- 263 12. Umefune G, Kogure H, Hamada T, Isayama H, Ishigaki K, Takagi K, et al. Procalcitonin  
264 is a useful biomarker to predict severe acute cholangitis: a single-center prospective study.  
265 *Journal of Gastroenterology.* 2017;52(6):734-45.
- 266 13. Suwa Y, Matsuyama R, Goto K, Kadokura T, Sato M, Mori R, et al. IL-7 and  
267 procalcitonin are useful biomarkers in the comprehensive evaluation of the severity of acute  
268 cholangitis. *J Hepatobiliary Pancreat Sci.* 2017;24(2):81-8.
- 269 14. Lee YS, Cho KB, Park KS, Lee JY, Lee YJ. Procalcitonin as a Decision-Supporting  
270 Marker of Urgent Biliary Decompression in Acute Cholangitis. *Digestive Diseases and Sciences.*

271 2018;63(9):2474-9.

272 15. Yokoe M, Takada T, Strasberg SM, Solomkin JS, Mayumi T, Gomi H, et al. TG13  
273 diagnostic criteria and severity grading of acute cholecystitis (with videos). J Hepatobiliary  
274 Pancreat Sci. 2013;20(1):35-46.

275 16. McGowan J, Straus S, Moher D, Langlois EV, O'Brien KK, Horsley T, et al. Reporting  
276 scoping reviews-PRISMA ScR extension. J Clin Epidemiol. 2020;123:177-9.

277 17. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA  
278 Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med.  
279 2018;169(7):467-73.

280 18. Lyu Y, Jiang H, Wang B, Yueming X, Weibing D, Cheng Y. The role of procalcitonin in  
281 patients with different severity grades of acute cholangitis. Chinese Journal of Hepatobiliary  
282 Surgery. 2014;20(6):428-30.

283 19. Korekawa K, Oki M, Kumimitsu A. Evaluation of the Usefulness of Procalcitonin as a  
284 Biomarker for the Diagnosis of Acute Cholangitis. Journal of Abdominal Emergency Medicine.  
285 2020;40(7):809-16.

286 20. Mayumi T, Okamoto K, Takada T, Strasberg SM, Solomkin JS, Schlossberg D, et al.  
287 Tokyo Guidelines 2018: management bundles for acute cholangitis and cholecystitis. J  
288 Hepatobiliary Pancreat Sci. 2018;25(1):96-100.



289 21. Wada K, Takada T, Kawarada Y, Nimura Y, Miura F, Yoshida M, et al. Diagnostic  
290 criteria and severity assessment of acute cholangitis: Tokyo Guidelines. J Hepatobiliary Pancreat  
291 Surg. 2007;14(1):52-8.

292 22. Kiriyaama S, Kozaka K, Takada T, Strasberg SM, Pitt HA, Gabata T, et al. Tokyo  
293 Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos). J  
294 Hepatobiliary Pancreat Sci. 2018;25(1):17-30.

295

296

297

298

299

300

301

302

303

304

305

306

307 **Table 1. Main characteristics of the included studies in the scoping reviews**

Author Year Country	Study Type	Aim	Outcome	Population	Comparative Groups	Key Findings	Limitations
Hamano et al. 2013 Japan	CC	To evaluate the usefulness of PCT for AC severity assessment	Serum PCT value	Severe AC (n = 26)	Mild (n = 39) and moderate (n = 94) AC	PCT was significantly higher in patients with severe AC than those with mild or moderate (p < 0.0001)	No cut-off for early/urgent biliary drainage. Other infections not excluded at the baseline
Korekawa et al. 2020 Japan	CC	To evaluate the usefulness of PCT to diagnose AC, and to determine a management plan	Serum PCT value Urgent biliary decompression Blood culture positivity	Severe AC (n = 7)	Mild (n = 57) and moderate (n = 58) AC	PCT was significantly higher in patients with severe AC than those with mild or moderate (p < 0.0001) Platelet was significantly lower in those with PCT of more than 1.3 ng/mL	Only seven severe AC patients were included
Lee et al. 2018 South Korea	CC	To determine the association of serum PCT with AC severity and clinical deterioration	Positive blood culture Method of biliary decompression Timing of biliary decompression	Severe AC (n = 26)	Mild (n = 39) and moderate (n = 139) AC	PCT was significantly higher in patients with severe AC than those with mild or moderate (p = 0.001) Patients who progressed to septic shock had significantly higher PCT than others (p = 0.040) No significant difference in timing of biliary decompression between groups (p = 0.341) Patients with positive blood culture (n = 65) had significantly higher	Considerable portion of patients with malignant stricture (n = 20, 9.8%) 95%CI for IQR not listed Only 6 (2.9%) patients had septic shock

							PCT than those with negative blood culture (p = 0.001)	
Lyu et al. 2014 China	CC	To evaluate the role of PCT to assess the severity of AC	Serum PCT value	Severe AC (n = 28)	Mild (n = 70) and moderate (n = 49) AC		PCT was significantly higher in patients with severe AC than those with mild or moderate (p < 0.05)	Retrospective data from a single center
Shinya et al. 2014 Japan	CC	To evaluate the correlation of AC severity and serum PCT	Serum PCT value Blood culture positivity	Severe AC (n = 25)	Mild (n = 22) and moderate (n = 63) AC		<p>PCT was significantly higher in patients with severe AC than those with mild AC (p &lt; 0.001)</p> <p>Those with positive blood culture (n = 13) had significantly higher PCT than those with negative blood culture (n = 59; p = 0.001)</p> <p>In patients with mild or moderate AC, those with purulent bile juice on ERCP (n = 24) had significantly higher PCT than those with normal bile juice from the duodenal papilla (n = 48; p &lt; 0.001)</p>	All included patients had AC due to choledocholithiasis. Blood culture was obtained only in 72 patients
Umefune et al. 2017 Japan	CC (prospective)	To evaluate the correlation between serum PCT on admission and severity	AC severity (TG13) The ability of PCT to predict severe AC due to	Severe AC (n = 29)	Mild (n = 108) and moderate (n = 76) AC		<p>Patients with multiple causes of AC included (n = 107 with stent occlusion, n = 82 with choledocholithiasis, n = 24 with other)</p> <p>PCT was significantly higher in patients with</p>	Small sample size to limit the robustness of secondary analyses. Data from a single tertiary care center causing a bias in the characteristics of the enrolled patients

---

of AC	choledocholithiasis/stent occlusion/positive blood culture	severe AC than those with mild AC ( $p < 0.0001$ )
	Timing of biliary decompression	Those with positive blood culture ( $n = 58$ ) had significantly higher PCT than those with negative blood culture ( $n = 112$ ; $p < 0.0001$ )
		Those with severe AC had urgent biliary drainage (within 6 hours from admission) more frequently than those with mild or moderate AC ( $p = 0.0096$ )

---

308 Abbreviations: AC, acute cholangitis; CC, case control; ERCP, endoscopic retrograde cholangiopancreatography; IQR, interquartile range; PCT,

309 procalcitonin; TG, Tokyo Guidelines

310

311

312

313

314

315

316

317

318

319

320

321

322

323

**Table 2. Key findings related to serum procalcitonin levels in the included studies**

Author Year Country	Severity Criteria Used	PCT – median (ng/mL)			Cut-off PCT for urgent biliary decompression (ng/mL)	Key Findings
		Mild AC	Moderate AC	Severe AC		
Hamano et al. 2013 Japan	TG07	0.08 (IQR; 0.04–0.18)	0.37 (IQR; 0.15–1.85)	5.56 (IQR; 3.59–25.89)	N/A	Cut-off PCT for severe AC: 3.1 ng/mL (sensitivity 80.8%, specificity 84.6%, OR 23.1 [95% CI 8.0–70.2]) AU-ROC of PCT for severe vs. mild to moderate AC = 0.86 (95% CI 0.78–0.92)
Korekawa et al. 2020 Japan	TG13	0.9 (IQR; 0.1–1.1)	9.9 (IQR; 1.2–15.9)	37.8 (IQR; 20.3–54.9)	N/A (cut-off PCT to predict those with lower platelet, who might be complicated with DIC and potential candidates for urgent biliary decompression)	AU-ROC of PCT for severe and moderate vs. mild AC = 0.89 (95% CI 0.84–0.95); no cut-off value provided Median PCT of those with positive blood culture: 12.7 ng/mL (IQR, 0.45–19.8) vs. 4.6 ng/mL (IQR, 0.2–4.9) in those with negative blood culture Cut-off PCT for positive blood culture: 1.3 ng/mL (sensitivity 67.0%, specificity 55.0%) Those with PCT > 1.3 ng/mL had significantly lower platelet than others (p < 0.0001)
Lee et al. 2018 South Korea	TG13	0.22 (IQR; 0.52)	1.35 (IQR; 4.67)	9.41 (IQR, 53.69)	N/A	Median PCT of those with positive blood culture: 3.25 ng/mL (IQR, 8.86) vs. 0.62 ng/mL (IQR, 3.78) in those with negative blood culture Median PCT of those progressed to septic shock: 9.11 ng/mL (IQR, 18.52) vs. 0.89 ng/mL (IQR, 4.34) in others Cut-off PCT for severe AC / septic shock: 1.76 ng/mL (sensitivity 84.6%, specificity 62.4%) / 3.77 ng/mL (sensitivity 80.0%, specificity 74.0%)

						AU-ROC of PCT for severe vs. mild to moderate AC = 0.778 (95% CI 0.680–0.876)
Lyu et al. 2014 China	TG13	0.166 (mean; SD ± 0.033)	0.349 (mean; SD ± 0.046)	0.759 (mean; SD ± 0.029)	N/A	Cut-off PCT for severe AC / moderate AC: 2.38 ng/mL (sensitivity 78.9%, specificity 73.7%) / 0.162 ng/mL (sensitivity 75.0%, specificity 61.1%)
Shinya et al. 2014 Japan	TG13	0.2 (IQR; 0.1–0.7)	0.7 (IQR; 0.2–2.7)	6.8 (IQR; 0.5–48.3)	N/A (cut-off PCT to predict those with purulent bile juice from the duodenal papilla was noted)	Cut-off PCT for severe AC: 2.33 ng/mL (sensitivity 64.0%, specificity 78.0%) AU-ROC of PCT for severe AC = 0.75 (95% CI 0.63–0.87) Median PCT of those with purulent bile juice: 7.9 ng/mL (IQR; 1.2–37.7) vs. 0.6 (IQR; 0.2–2.9) in those with normal bile juice Cut-off PCT for purulent bile juice: 3.2 ng/mL (sensitivity 67.0%, specificity 79.0%) AU-ROC of PCT for purulent bile juice = 0.77 (95% CI 0.64–0.89)
Umefune et al. 2017 Japan	TG13	0.45 (IQR; 0.22–1.69)	1.25 (IQR; 0.41–4.18)	19.51 (IQR; 4.41–53.36)	N/A	Cut-off PCT for severe AC: 2.2 ng/mL (sensitivity 97.0%, specificity 73.0%) AU-ROC of PCT for severe AC = 0.90 (95% CI 0.85–0.96); better than WBC or CRP Median PCT of those with positive blood culture: 4.71 ng/mL (IQR, 0.87–16.96) vs. 0.65 ng/mL (IQR, 0.25–2.26) in those with negative blood culture

324 Abbreviations: AC, acute cholangitis; AU-ROC, area under the receiver operator characteristic; CI, confidence interval; CRP, C-reactive protein;  
 325 DIC, disseminated intravascular coagulopathy; IQR, interquartile range; OR, odds ratio; PCT, procalcitonin; SD, standard deviation; TG, Tokyo  
 326 Guidelines; WBC, white blood cell

327

328

329

330 **Figure Legends**

331 **Figure 1. PRISMA flowchart of the search strategy**

**Figure 1**

Identification

Screening

Eligibility

Included

